Related references
Note: Only part of the references are listed.The role of endoglin in post-ischemic revascularization
Elena Nunez-Gomez et al.
ANGIOGENESIS (2017)
Cancer incidence in patients with hereditary hemorrhagic telangiectasia
Christine W. Duarte et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Macro- and microvascular endothelial dysfunction in diabetes
Yi Shi et al.
JOURNAL OF DIABETES (2017)
Endoglin regulates mural cell adhesion in the circulatory system
Elisa Rossi et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Electrotransfer of Plasmid DNA Encoding an Anti-Mouse Endoglin (CD105) shRNA to B16 Melanoma Tumors with Low and High Metastatic Potential Results in Pronounced Anti-Tumor Effects
Tanja Dolinsek et al.
CANCERS (2016)
Tumor radiosensitization by gene therapy against endoglin
M. Stimac et al.
CANCER GENE THERAPY (2016)
Modulating the Vascular Response to Limb Ischemia Angiogenic and Cell Therapies
John P. Cooke et al.
CIRCULATION RESEARCH (2015)
Gene therapy in peripheral artery disease
Fumihiro Sanada et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations?
Jose M. Munoz-Felix et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects
Monika Stimac et al.
PLOS ONE (2015)
Endoglin (CD105) Silencing Mediated by shRNA Under the Control of Endothelin-1 Promoter for Targeted Gene Therapy of Melanoma
Natasa Tesic et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Mononuclear cells and vascular repair in HHT
Calinda K. E. Dingenouts et al.
FRONTIERS IN GENETICS (2015)
Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era
Jamie McDonald et al.
FRONTIERS IN GENETICS (2015)
Angiogenic and Inflammatory Vitreous Biomarkers Associated With Increasing Levels of Retinal Ischemia
Kyle Kovacs et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2015)
Improved Survival Outcomes in Cancer Patients with Hereditary Hemorrhagic Telangiectasia
Christine W. Duarte et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
HIF-1α and HIF-2α induce angiogenesis and improve muscle energy recovery
Henna Niemi et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2014)
A review of anti-VEGF agents for proliferative diabetic retinopathy
P. Osaadon et al.
EYE (2014)
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology
Yingmiao Liu et al.
INVESTIGATIONAL NEW DRUGS (2014)
Endoglin for Targeted Cancer Treatment
Lee S. Rosen et al.
CURRENT ONCOLOGY REPORTS (2014)
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer
Yingmiao Liu et al.
CANCER MEDICINE (2014)
Endoglin Promotes Angiogenesis in Cell- and Animal-Based Models of Retinal Neovascularization
Joshua M. Barnett et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration
Elisa Rossi et al.
BLOOD (2013)
Endoglin for tumor imaging and targeted cancer therapy
Madelon Paauwe et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Endoglin regulates the activation and quiescence of endothelium by participating in canonical and non-canonical TGF-β signaling pathways
SunYoung Park et al.
JOURNAL OF CELL SCIENCE (2013)
Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
Charlotte Anderberg et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Therapeutic angiogenesis for critical limb ischaemia
Brian H. Annex
NATURE REVIEWS CARDIOLOGY (2013)
Angiogenesis and Its Therapeutic Opportunities
So Young Yoo et al.
MEDIATORS OF INFLAMMATION (2013)
POSTISCHEMIC REVASCULARIZATION: FROM CELLULAR AND MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS
Jean-Sebastien Silvestre et al.
PHYSIOLOGICAL REVIEWS (2013)
Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls
Anna E. Hosman et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Multiple Delivery of siRNA against Endoglin into Murine Mammary Adenocarcinoma Prevents Angiogenesis and Delays Tumor Growth
Tanja Dolinsek et al.
PLOS ONE (2013)
Oxysterol-Induced Soluble Endoglin Release and Its Involvement in Hypertension
Ana C. Valbuena-Diez et al.
CIRCULATION (2012)
High Immunohistochemical Expression of TGF-β1 Predicts a Poor Prognosis in Cervical Cancer Patients who Harbor Enriched Endoglin Microvessel Density
Hao Lin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2012)
Shear induced collateral artery growth modulated by endoglin but not by ALK1
Leonard Seghers et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Endoglin Requirement for BMP9 Signaling in Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies
Olivier Nolan-Stevaux et al.
PLOS ONE (2012)
Therapeutic angiogenesis: controlled delivery of angiogenic factors
Hunghao Chu et al.
THERAPEUTIC DELIVERY (2012)
The Pathogenesis of Systemic Sclerosis
Tamiko R. Katsumoto et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Coordinating cell behaviour during blood vessel formation
Ilse Geudens et al.
DEVELOPMENT (2011)
Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects
Ian Zachary et al.
HEART (2011)
Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor Growth
Roselyne Castonguay et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis
Jana Rathouska et al.
PHARMACOLOGICAL RESEARCH (2011)
Concise Review: Circulating Endothelial Progenitor Cells for Vascular Medicine
Takayuki Asahara et al.
STEM CELLS (2011)
Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors
Patricia Kuiper et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients
Ana M. Blazquez-Medela et al.
BMC MEDICINE (2010)
Pathogenesis of Arteriovenous Malformations in the Absence of Endoglin
Marwa Mahmoud et al.
CIRCULATION RESEARCH (2010)
Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia
Franck Lebrin et al.
NATURE MEDICINE (2010)
Cellular and molecular aspects of vascular dysfunction in systemic sclerosis
Maria Trojanowska
NATURE REVIEWS RHEUMATOLOGY (2010)
Long-Term Outcome of Therapeutic Neovascularization Using Peripheral Blood Mononuclear Cells for Limb Ischemia
Junji Moriya et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2009)
Mechanisms of Disease: Scleroderma.
Armando Gabrielli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia
Satoaki Matoba et al.
AMERICAN HEART JOURNAL (2008)
Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing
Zhao-Jun Liu et al.
ANTIOXIDANTS & REDOX SIGNALING (2008)
Results of a double-blind, placebo-controlled Study to Assess the Safety of Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb Perfusion in Patients with Critical Limb Ischemia
Richard J. Powell et al.
CIRCULATION (2008)
L- and S-endoglin differentially modulate TGFβ1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts
Soraya Velasco et al.
JOURNAL OF CELL SCIENCE (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
A role for endoglin as a suppressor of malignancy during mouse skin carcinogenesis
Eduardo Perez-Gomez et al.
CANCER RESEARCH (2007)
Endoglin has a crucial role in blood cell-mediated vascular repair
Linda W. van Laake et al.
CIRCULATION (2006)
Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy
Stephen Kolakowski et al.
JOURNAL OF CARDIAC SURGERY (2006)
Reduced angiogenic responses in adult endoglin heterozygous mice
M Jerkic et al.
CARDIOVASCULAR RESEARCH (2006)
Soluble endoglin contributes to the pathogenesis of preeclampsia
Shivalingappa Venkatesha et al.
NATURE MEDICINE (2006)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
Aging and angiogenesis
JM Edelberg et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2003)
CD105 prevents apoptosis in hypoxic endothelial cells
CG Li et al.
JOURNAL OF CELL SCIENCE (2003)
Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: Design of the RAVE trial
S Rajagopalan et al.
AMERICAN HEART JOURNAL (2003)
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
RJ Lederman et al.
LANCET (2002)
Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease
M Vasa et al.
CIRCULATION RESEARCH (2001)
Mobilization of endothelial progenitor cells in patients with acute myocardial infarction
S Shintani et al.
CIRCULATION (2001)
Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice
GC Schatteman et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Endoglin, an ancillary TGF beta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development
HM Arthur et al.
DEVELOPMENTAL BIOLOGY (2000)
Share Paper
